Literature DB >> 26561941

Comorbidity variation in patients with obsessive-compulsive disorder according to symptom dimensions: Results from a large multicentre clinical sample.

Albina R Torres1, Leonardo F Fontenelle2, Roseli G Shavitt3, Ygor A Ferrão4, Maria Conceição do Rosário5, Eric A Storch6, Euripedes C Miguel3.   

Abstract

BACKGROUND: Obsessive-compulsive disorder (OCD) has a heterogeneous and complex phenomenological picture, characterized by different symptom dimensions and comorbid psychiatric disorders, which frequently co-occur or are replaced by others over the illness course. To date, very few studies have investigated the associations between specific OCD symptom dimensions and comorbid disorders.
METHODS: Cross-sectional, multicenter clinical study with 1001 well-characterized OCD patients recruited within the Brazilian Research Consortium on Obsessive-Compulsive and Related Disorders. The primary instruments were the Dimensional Yale-Brown Obsessive Compulsive Scale (DY-BOCS) and the Structured Clinical Interview for DSM-IV Axis I Disorders. Bivariate analyses between symptom dimensions and comorbidities were followed by logistic regression.
RESULTS: The most common comorbidities among participants (56.8% females) were major depression (56.4%), social phobia (34.6%), generalized anxiety disorder (34.3%), and specific phobia (31.4%). The aggressive dimension was independently associated with posttraumatic stress disorder (PTSD), separation anxiety disorder, any impulse-control disorder and skin picking; the sexual-religious dimension was associated with mood disorders, panic disorder/agoraphobia, social phobia, separation anxiety disorder, non-paraphilic sexual disorder, any somatoform disorder, body dysmorphic disorder and tic disorders; the contamination-cleaning dimension was related to hypochondriasis; and the hoarding dimension was associated with depressive disorders, specific phobia, PTSD, impulse control disorders (compulsive buying, skin picking, internet use), ADHD and tic disorders. The symmetry-ordering dimension was not independently associated with any comorbidity. LIMITATIONS: Cross-sectional design; participants from only tertiary mental health services; personality disorders not investigated.
CONCLUSIONS: Different OCD dimensions presented some specific associations with comorbid disorders, which may influence treatment seeking behaviors and response, and be suggestive of different underlying pathogenic mechanisms.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Comorbid disorders; Comorbidity; Obsessive–compulsive disorder; Symptom dimensions

Mesh:

Year:  2015        PMID: 26561941     DOI: 10.1016/j.jad.2015.10.051

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  15 in total

1.  Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Authors:  Elena Martín-González; Ángeles Prados-Pardo; Santiago Mora; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2018-01-08       Impact factor: 4.530

2.  A structural MRI study of excoriation (skin-picking) disorder and its relationship to clinical severity.

Authors:  Michael D Harries; Samuel R Chamberlain; Sarah A Redden; Brian L Odlaug; Austin W Blum; Jon E Grant
Journal:  Psychiatry Res Neuroimaging       Date:  2017-09-08       Impact factor: 2.376

3.  Co-occurring Attention Deficit Hyperactivity Disorder symptoms in adults affected by heroin dependence: Patients characteristics and treatment needs.

Authors:  Fabio Lugoboni; Frances Rudnick Levin; Maria Chiara Pieri; Matteo Manfredini; Lorenzo Zamboni; Lorenzo Somaini; Gilberto Gerra
Journal:  Psychiatry Res       Date:  2017-01-21       Impact factor: 3.222

4.  Fronto-Striatal Glutamate in Autism Spectrum Disorder and Obsessive Compulsive Disorder.

Authors:  Jilly Naaijen; Marcel P Zwiers; Houshang Amiri; Steven C R Williams; Sarah Durston; Bob Oranje; Daniel Brandeis; Regina Boecker-Schlier; Matthias Ruf; Isabella Wolf; Tobias Banaschewski; Jeffrey C Glennon; Barbara Franke; Jan K Buitelaar; David J Lythgoe
Journal:  Neuropsychopharmacology       Date:  2016-11-21       Impact factor: 7.853

5.  Parental bonding and hoarding in obsessive-compulsive disorder.

Authors:  David Chen; O Joseph Bienvenu; Janice Krasnow; Ying Wang; Marco A Grados; Bernadette Cullen; Fernando S Goes; Brion Maher; Benjamin D Greenberg; Nicole C McLaughlin; Steven A Rasmussen; Abby J Fyer; James A Knowles; James T McCracken; John Piacentini; Dan Geller; David L Pauls; S Evelyn Stewart; Dennis L Murphy; Yin-Yao Shugart; Mark A Riddle; Gerald Nestadt; Jack Samuels
Journal:  Compr Psychiatry       Date:  2016-11-14       Impact factor: 3.735

6.  Unhealthy Alcohol Use Associated with Obsessive-Compulsive Symptoms: The Moderating Effects of Anxiety and Depression.

Authors:  Michael P Randazza; Dean McKay; Jafar Bakhshaie; Eric A Storch; Michael J Zvolensky
Journal:  J Obsessive Compuls Relat Disord       Date:  2022-02-08       Impact factor: 1.677

7.  Obsessive Compulsive Disorder and Bipolar Disorder Comorbidity: A Comparative Study.

Authors:  Mohammadrasoul Khalkhali; Safarali Vaghari; Roghaye Zare; Seyed Mousa Kafi Masouleh
Journal:  Iran J Psychiatry       Date:  2022-04

Review 8.  Peromyscus maniculatus bairdii as a naturalistic mammalian model of obsessive-compulsive disorder: current status and future challenges.

Authors:  De Wet Wolmarans; Isabella M Scheepers; Dan J Stein; Brian H Harvey
Journal:  Metab Brain Dis       Date:  2017-12-06       Impact factor: 3.584

9.  Symptom dimensions in obsessive-compulsive disorder as predictors of neurobiology and treatment response.

Authors:  Anders Lillevik Thorsen; Gerd Kvale; Bjarne Hansen; Odile A van den Heuvel
Journal:  Curr Treat Options Psychiatry       Date:  2018-02-23

Review 10.  A dimensional perspective on the genetics of obsessive-compulsive disorder.

Authors:  Nora I Strom; Takahiro Soda; Carol A Mathews; Lea K Davis
Journal:  Transl Psychiatry       Date:  2021-07-21       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.